190 related articles for article (PubMed ID: 32815181)
1. Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.
Roth NJ; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gröner A; Gustafson M; Jorquera JI; Kreil TR; Misztela D; Moretti E; Moscardini M; Poelsler G; More J; Roberts P; Wieser A; Gajardo R
Transfusion; 2020 Nov; 60(11):2661-2674. PubMed ID: 32815181
[TBL] [Abstract][Full Text] [Related]
2. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
3. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
4. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
5. Robustness of nanofiltration for increasing the viral safety margin of biological products.
Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
[TBL] [Abstract][Full Text] [Related]
6. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process.
Van Holten RW; Ciavarella D; Oulundsen G; Harmon F; Riester S
Vox Sang; 2002 Oct; 83(3):227-33. PubMed ID: 12366764
[TBL] [Abstract][Full Text] [Related]
8. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration.
Omar A; Kempf C
Transfusion; 2002 Aug; 42(8):1005-10. PubMed ID: 12385411
[TBL] [Abstract][Full Text] [Related]
9. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
10. Virus removal capacity at varying ionic strength during nanofiltration of AlphaNine® SD.
Jorba N; Shitanishi KT; Winkler CJ; Herring SW
Biologicals; 2014 Sep; 42(5):290-3. PubMed ID: 24999080
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
[TBL] [Abstract][Full Text] [Related]
12. Extent of hepatitis E virus elimination is affected by stabilizers present in plasma products and pore size of nanofilters.
Yunoki M; Yamamoto S; Tanaka H; Nishigaki H; Tanaka Y; Nishida A; Adan-Kubo J; Tsujikawa M; Hattori S; Urayama T; Yoshikawa M; Yamamoto I; Hagiwara K; Ikuta K
Vox Sang; 2008 Aug; 95(2):94-100. PubMed ID: 18714441
[TBL] [Abstract][Full Text] [Related]
13. Protein sieving characteristics of sub-20-nm pore size filters at varying ionic strength during nanofiltration of Coagulation Factor IX.
Winkler CJ; Jorba N; Shitanishi KT; Herring SW
Biologicals; 2013 May; 41(3):176-83. PubMed ID: 23410583
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus].
Oh DJ; Lee YL; Kang JW; Kwon SY; Cho NS; Kim IS
Korean J Lab Med; 2010 Feb; 30(1):45-50. PubMed ID: 20197722
[TBL] [Abstract][Full Text] [Related]
15. Effective inactivation of a wide range of viruses by pasteurization.
Gröner A; Broumis C; Fang R; Nowak T; Popp B; Schäfer W; Roth NJ
Transfusion; 2018 Jan; 58(1):41-51. PubMed ID: 29148053
[TBL] [Abstract][Full Text] [Related]
16. Antibody-enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin.
Kapsch AM; Farcet MR; Wieser A; Ahmad MQ; Miyabayashi T; Baylis SA; Blümel J; Kreil TR
Transfusion; 2020 Nov; 60(11):2500-2507. PubMed ID: 32794187
[TBL] [Abstract][Full Text] [Related]
17. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance.
Parkkinen J; Rahola A; von Bonsdorff L; Tölö H; Törmä E
Vox Sang; 2006 Feb; 90(2):97-104. PubMed ID: 16430667
[TBL] [Abstract][Full Text] [Related]
18. Validation and implementation of Planova™ BioEX virus filters in the manufacture of a new liquid intravenous immunoglobulin in China.
Ma S; Pang GL; Shao YJ; Hongo-Hirasaki T; Shang MX; Inouye M; Jian CY; Zhu MZ; Yang HH; Gao JF; Xi ZY; Song DW
Biologicals; 2018 Mar; 52():37-43. PubMed ID: 29434001
[TBL] [Abstract][Full Text] [Related]
19. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
20. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
